
Esperion Therapeutics Inc
NASDAQ:ESPR

Intrinsic Value
The intrinsic value of one
ESPR
stock under the Base Case scenario is
4.8
USD.
Compared to the current market price of 1.17 USD,
Esperion Therapeutics Inc
is
Undervalued by 76%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Esperion Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Esperion Therapeutics Inc
Balance Sheet Decomposition
Esperion Therapeutics Inc
Current Assets | 318.8m |
Cash & Short-Term Investments | 114.6m |
Receivables | 81.3m |
Other Current Assets | 122.9m |
Non-Current Assets | 5.3m |
PP&E | 5.2m |
Intangibles | 56k |
Free Cash Flow Analysis
Esperion Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Esperion Therapeutics Inc
Revenue
|
259.6m
USD
|
Cost of Revenue
|
-90.1m
USD
|
Gross Profit
|
169.5m
USD
|
Operating Expenses
|
-264.4m
USD
|
Operating Income
|
-94.9m
USD
|
Other Expenses
|
-58.3m
USD
|
Net Income
|
-153.2m
USD
|
ESPR Profitability Score
Profitability Due Diligence
Esperion Therapeutics Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Score
Esperion Therapeutics Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
ESPR Solvency Score
Solvency Due Diligence
Esperion Therapeutics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Score
Esperion Therapeutics Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ESPR Price Targets Summary
Esperion Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ESPR
is 5.9 USD
with a low forecast of 1.52 USD and a high forecast of 16.8 USD.
Dividends
Current shareholder yield for ESPR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ESPR
stock under the Base Case scenario is
4.8
USD.
Compared to the current market price of 1.17 USD,
Esperion Therapeutics Inc
is
Undervalued by 76%.